371 related articles for article (PubMed ID: 7053859)
1. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.
Coezy E; Borgna JL; Rochefort H
Cancer Res; 1982 Jan; 42(1):317-23. PubMed ID: 7053859
[TBL] [Abstract][Full Text] [Related]
2. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
[TBL] [Abstract][Full Text] [Related]
3. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
Miller MA; Lippman ME; Katzenellenbogen BS
Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
5. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
[TBL] [Abstract][Full Text] [Related]
6. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents.
Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR
Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397
[TBL] [Abstract][Full Text] [Related]
8. Influence of different combinations of tamoxifen and toremifene on estrogen receptor-positive breast cancer cell lines.
Coradini D; Biffi A; Cappelletti V; Di Fronzo G
Cancer Detect Prev; 1995; 19(4):348-54. PubMed ID: 7553677
[TBL] [Abstract][Full Text] [Related]
9. Interactions of antiestrogens with human breast cancer in long-term tissue culture.
Lippman M; Bolan G; Huff K
Cancer Treat Rep; 1976 Oct; 60(10):1421-9. PubMed ID: 1035504
[TBL] [Abstract][Full Text] [Related]
10. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.
Gottardis MM; Robinson SP; Satyaswaroop PG; Jordan VC
Cancer Res; 1988 Feb; 48(4):812-5. PubMed ID: 3338079
[TBL] [Abstract][Full Text] [Related]
11. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
12. Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro.
Reddel RR; Murphy LC; Sutherland RL
Cancer Res; 1983 Oct; 43(10):4618-24. PubMed ID: 6883318
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen.
Taylor CM; Blanchard B; Zava DT
Cancer Res; 1984 Apr; 44(4):1409-14. PubMed ID: 6704959
[TBL] [Abstract][Full Text] [Related]
14. Species-specific pharmacology of antiestrogens: role of metabolism.
Jordan VC; Robinson SP
Fed Proc; 1987 Apr; 46(5):1870-4. PubMed ID: 3556610
[TBL] [Abstract][Full Text] [Related]
15. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
16. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites.
Watts CK; Sutherland RL
Mol Pharmacol; 1987 May; 31(5):541-51. PubMed ID: 3553893
[TBL] [Abstract][Full Text] [Related]
17. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
[TBL] [Abstract][Full Text] [Related]
18. Physicochemical and genetic evidence for specific antiestrogen binding sites.
Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477
[TBL] [Abstract][Full Text] [Related]
19. Regulation of estrogen and progestin receptor concentrations in an experimental rat prostatic carcinoma by estrogen, antiestrogen, and progesterone.
Mobbs BG; Johnson IE; DeSombre ER; Toth J; Hughes A
Cancer Res; 1987 May; 47(10):2645-51. PubMed ID: 3552202
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen derivatives for delivery of the antitumoral (DACH)Pt group: selective synthesis by McMurry coupling, and biochemical behaviour.
Top S; Kaloun el B; Vessières A; Leclercq G; Laïos I; Ourevitch M; Deuschel C; McGlinchey MJ; Jaouen G
Chembiochem; 2003 Aug; 4(8):754-61. PubMed ID: 12898627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
